Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer’s disease assessment: findings from the Apollo study
Elecsys CSF ratios and Aβ<sub>42</sub> alone may be reliable alternatives to amyloid PET for identifying amyloid positivity in clinical practice.
Authors
- Jan-Philipp Weinberger
- Magnus Förnvik Jonsson (ORCID: https://orcid.org/0000-0002-9227-744X)
- Sandra Rutz
- Henrik Schinke
- Stefanie Gaupp
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Ekaterina Manuilova
- Rikard Nilsson
- Margherita Carboni (ORCID: https://orcid.org/0000-0003-0426-8242)
- Mayme Gummesson
- Silja McIlwrick
Institutions
- Roche (Switzerland) (CH)
- Malmö University (SE)
- Lund University (SE)
- Roche Pharma AG (Germany) (DE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1515/cclm-2024-1476
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94